Home » Stocks » Aptose Biosciences

Aptose Biosciences, Inc. (APTO)

Stock Price: $5.20 USD 0.14 (2.77%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $5.10 -0.10 (-1.92%) Aug 3, 6:15 PM

Stock Price Chart

Key Info

Market Cap 451.22M
Revenue (ttm) n/a
Net Income (ttm) -32.30M
Shares Out 86.77M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $5.20
Previous Close $5.06
Change ($) 0.14
Change (%) 2.77%
Day's Open 5.14
Day's Range 5.06 - 5.26
Day's Volume 944,692
52-Week Range 1.82 - 9.25

More Stats

Market Cap 451.22M
Enterprise Value 362.66M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 86.77M
Float 59.06M
EPS (basic) -0.53
EPS (diluted) -0.55
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.61M
Short Ratio 2.93
Short % of Float 2.34%
Beta 0.97
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.03
Revenue n/a
Operating Income -33.09M
Net Income -32.30M
Free Cash Flow -24.89M
Net Cash 88.56M
Net Cash / Share 1.02
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -36.84%
ROE -62.92%
ROIC -196.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(117.12% upside)
Current: $5.20
Target: 11.29
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.86-29.11-11.83-14.27-12.86-10.33-5.59-4.60
Net Income-26.28-28.87-11.64-14.24-11.71-10.55-5.57-4.61
Shares Outstanding50.1633.3922.3112.7411.915.223.521.69
Earnings Per Share-0.52-0.86-0.52-1.12-0.98-2.02-1.58-2.76
Operating Cash Flow-21.56-23.21-10.22-12.39-9.89-8.54-5.09-3.31
Capital Expenditures-0.10-0.33-0.01--0.26-0.02--
Free Cash Flow-21.66-23.54-10.24-12.39-10.15-8.56-5.09-3.31
Cash & Equivalents97.6015.7411.437.9414.2730.390.650.00
Total Debt1.53----0.53--
Net Cash / Debt96.0715.7411.437.9414.2729.860.650.00
Book Value93.9314.0810.207.3313.6528.44-0.78-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aptose Biosciences, Inc.
Country Canada
Employees 31
CEO William G. Rice

Stock Information

Ticker Symbol APTO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: APTO


Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.